top of page

Rubix LS Nominated for Prestigious DEI Award

Rubix LS is among an illustrious group of finalists for an award in the Diversity and Inclusion (DI) Champions category from the BWB Awards, recognizing excellence and leadership in the healthcare industry, the company announced last week.

As part of Biotech Week Boston, the award ceremony highlights innovative achievements from several companies in several categories, including Biology Breakthrough, Digital Medicine, and recognizing individual leaders and lifetime achievement designations.

The DI category spotlighted the outstanding work of individual or group initiatives that championed equality, diversity, and inclusion within their organizations or the broader life sciences space.

“I believe this nomination is less about me and the team at Rubix LS and more of a recognition that diversity, equity, and inclusion have never been more important to promote in clinical trials, and more broadly in America,” Rubix LS CEO Reginald Swift said. “Win or lose, it’s an honor to be nominated. I hope to use this platform to continue raising awareness about the need to widen clinical trial participation, so all Americans benefit from new treatments and devices alleviating suffering and prolonging quality lives,” he added.

Judges include Joe Boncore, CEO at MassBio, Melinda Richter, Global Head, Johnson & Johnson Innovation at JLABS, Laurie Glimcher, President & CEO at Dana Farber Cancer Institute, and Craig Martin, CEO, Global Genes.

Winners will be announced on September 27.

“At Rubix LS, we remain committed to giving more people access to clinical trials and benefitting from innovative drugs, devices, and other therapies designed to help everyone live richer fuller lives,” Swift said. “This nomination inspires us to work toward even greater heights in the future,” he added.

bottom of page